101P Potential immune-oncological effect of liposomal-doxorubicin in breast cancer via tumor microenvironment alteration

After invasive ductal carcinoma, lobular carcinoma (ILC) is the most frequent breast cancer and accounts for nearly 15% of all cancers (BC). Doxorubicin (DXR) a very effective chemotherapeutic drug utilized to treat BC but induces resistance severe side effects. Recently, liposomes have gained popularity as tumor microenvironment (TME) modulatory anticancer agents various malignancies, including BC. This study propose liposomal-DXR combination produce an immune-responsive regulatory effect on competing endogenous RNAs (ceRNAs) through alteration in TME investigate immunological impact via regulation ceRNAs immune cytokines at cells. MDA-MB cells were treated with varying concentration dose response curve was calculated. Total RNA extracted quantified by qRT-PCR TNF-α ELISA kit. Computational target interaction analyzed. Treatment resulted time-dependent cell-viability migration inhibition. altered level AKT1, ESR1, ARID1A genes. Alteration miR-17-5p compared control indicated network. found repressed Present mechanism potential modulatory, immunoregulatory anti-ILC agent altering circuit, genes,